VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
VKTX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
VKTXViking Therapeutics, Inc.
$39.54$4.6B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksVKTXBalance Sheet

Viking Therapeutics, Inc. (VKTX) Balance Sheet

14Y historyFree accessUpdated daily

Viking Therapeutics, Inc. (VKTX) annual balance sheet — 14-year assets, liabilities & equity history

VKTX Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Total Current Assets608.21M715.6M907.22M367.23M167.04M210.53M256.1M283.5M302.13M21.85M13.97M15.2M773.68K179.62K0
Cash & Short-Term Investments602.96M705.74M902.61M362.08M155.49M202.1M248.39M275.64M301.52M20.58M13.15M14.1M755.86K179.62K0
Cash Only118.12M165.81M26.68M55.52M36.63M26.37M29.12M8.38M24.78M8.99M3.08M768.55K755.86K179.62K0
Short-Term Investments484.85M539.93M875.94M306.56M118.85M175.73M219.27M267.26M276.74M11.59M10.08M13.34M000
Accounts Receivable000000000000000
Days Sales Outstanding---------------
Inventory000000000000000
Days Inventory Outstanding---------------
Other Current Assets1.22M9.86M1.13M2.52M8.14M7.81M7.28M7.46M0388.97K824.27K0000
Total Non-Current Assets33K131K1.1M1.26M1.49M134K399K755K179K269.61K560.88K237.46K2.27M7750
Property, Plant & Equipment085K1M1.13M1.42M25K321K598K0000000
Fixed Asset Turnover0.00x--------------
Goodwill000000000000000
Intangible Assets000000000000000
Long-Term Investments000000000000000
Other Non-Current Assets33K46K102K139K71K109K78K157K179K269.61K560.88K237.46K2.27M7750
Total Assets608.24M715.73M908.32M368.49M168.53M210.66M256.5M284.26M302.31M22.12M14.54M15.44M3.04M180.39K0
Asset Turnover0.00x--------------
Asset Growth %-84.78%-21.2%146.5%118.65%-20%-17.87%-9.76%-5.97%1266.6%52.19%-5.85%407.34%1586.94%--
Total Current Liabilities106.33M76.67M27.41M19.14M21.95M8.78M12.13M6.78M4.55M8.66M6.48M1.98M22.52M127.49K54.38K
Accounts Payable67.18M53.25M9.81M7.51M8.53M1.44M3.99M2.43M959K1.53M1.2M592.41K1.83M73.38K54.03K
Days Payables Outstanding57.18K45.1K-----3.41K-------
Short-Term Debt0000000003.45M3.27M0304.27K46.89K0
Deferred Revenue (Current)0000000002.28M1.27M020.32M00
Other Current Liabilities39.14M000000001.4M731.05K058.74K00
Current Ratio5.72x9.33x33.09x19.19x7.61x23.98x21.11x41.83x66.40x2.52x2.16x7.69x0.03x1.41x-
Quick Ratio5.72x9.33x33.09x19.19x7.61x23.98x21.11x41.83x66.40x2.52x2.16x7.69x0.03x1.41x-
Cash Conversion Cycle---------------
Total Non-Current Liabilities00630K936K1.26M029K360K12K4.98M16.31K4.74M2.65M303.51K51.04K
Long-Term Debt000000000002.15M1.26M231.85K42.75K
Capital Lease Obligations728K0630K936K1.26M029K360K0000000
Deferred Tax Liabilities000000000000000
Other Non-Current Liabilities0000000012K016.31K2.59M1.39M71.66K8.29K
Total Liabilities106.33M76.67M28.04M20.07M23.21M8.78M12.16M7.14M4.56M8.66M6.49M6.71M25.17M431K105.42K
Total Debt0137K1.12M1.26M1.56M29K359K662K03.45M3.27M2.15M1.57M278.75K42.75K
Net Debt-118.12M-165.67M-25.56M-54.26M-35.07M-26.34M-28.76M-7.71M-24.78M-5.54M194.08K1.38M812.53K99.13K42.75K
Debt / Equity0.00x0.00x0.00x0.00x0.01x0.00x0.00x0.00x-0.26x0.41x0.25x---
Debt / EBITDA-0.00x--------------
Net Debt / EBITDA0.24x--------------
Interest Coverage-15687.44x-7023.96x-1605.54x-1145.76x-1192.46x-3093.44x-371.59x-175.57x-38.26x-9.55x-6.25x-21.98x-37.33x-4.96x-
Total Equity501.92M639.06M880.28M348.42M145.32M201.88M244.34M277.12M297.75M13.46M8.04M8.72M-22.13M-250.6K-105.42K
Equity Growth %-103.54%-27.4%152.65%139.76%-28.02%-17.38%-11.83%-6.93%2111.32%67.41%-7.82%139.43%-8730.08%-137.73%-
Book Value per Share4.345.678.073.691.892.623.373.855.170.520.491.37-5.13-0.06-71.10
Total Shareholders' Equity501.92M639.06M880.28M348.42M145.32M201.88M244.34M277.12M297.75M13.46M8.04M8.72M-22.13M-250.6K-105.42K
Common Stock1K1K1K1K1K1K1K1K1K35820897605250
Retained Earnings-1.01B-847.55M-487.91M-377.94M-292.05M-223.18M-168.19M-128.7M-102.92M-80.85M-60.28M-45.55M-22.14M-257.27K-111.03K
Treasury Stock000-6.79M-6.79M0000000000
Accumulated OCI-856K378K-788K-389K-1.1M-549K-54K12K-423K-19.77K-6.89K-7.37K0-4.5K0
Minority Interest000000000000000

VKTX — Frequently Asked Questions

Quick answers to the most common questions about buying VKTX stock.

What are the total assets of Viking Therapeutics, Inc. (VKTX)?

As of 2025, Viking Therapeutics, Inc. (VKTX) had total assets of $715.7M including $715.6M in current assets.

How much debt does Viking Therapeutics, Inc. (VKTX) have?

Viking Therapeutics, Inc. (VKTX) carries total debt of $0.1M, offset by $705.7M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Viking Therapeutics, Inc.?

Viking Therapeutics, Inc. (VKTX) has total shareholders' equity (book value) of $639.1M ($5.67 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Viking Therapeutics, Inc.'s current ratio and liquidity?

Viking Therapeutics, Inc. (VKTX) reported a current ratio of 9.33x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.